ESMO: European Society for Medical Oncology

Conference Coverage

Nivolumab boosts overall survival in HCC

BARCELONA – Nivolumab led to clinically meaningful, but not statistically significant, improvement in OS and ORR vs. sorafenib for first-line...

Conference Coverage

PARP inhibitor prolongs PFS in mCRPC

BARCELONA – The PROfound trial shows that targeted therapy can be effective against metastatic castration-resistant prostate cancer bearing DNA...

Pages